Table 3.
Glioblastoma and lower-grade glioma samples.
| Antigen | Glioblastoma |
Lower-grade glioma |
||||||
|---|---|---|---|---|---|---|---|---|
| Sex (n/N) |
Mean age at operation (years) | Isocitrate dehydrogenase status (n/N) | Sex (n/N) |
Mean age at operation (years) | Isocitrate dehydrogenase status (n/N) | |||
| Female | Male | Female | Male | |||||
| TRIM28, TUFM, NUCL | 5/10 | 5/10 | 68 | 10/10 wild type | 4/8 | 4/8 | 48 | 7/8 mutant; 1/8 wild type |
| VIM | 6/11 | 5/11 | 68 | 10/10 wild type | 2/4 | 2/4 | 49 | 4/4 mutant |
| NAP1L1, DPYSL2, CRMP1, ALYREF | 6/11 | 5/11 | 68 | 10/10 wild type | 4/8 | 4/8 | 48 | 7/8 mutant; 1/8 wild type |
ALYREF, Aly/REF export factor; CRMP1, collapsin response mediator protein 1; DPYSL2, dihydropyrimidinase-related protein 2; NAP1L1, nucleosome assembly protein 1-like 1; NUCL, nucleolin; RPL13A, ribosomal protein L13a; TRIM28, tripartite motif containing 28 protein; TUFM, mitochondrial translation elongation factor (EF-TU); VIM, vimentin.